Harpreet Singh. (via Allogeneic Cell Therapies Summit)
Immatics scores $75M upfront in TCR deal with Celgene as interest in tech burgeons
Months after elevating its chief scientist, Harpreet Singh, to the post of CEO, privately-held immuno-oncology company Immatics has enlisted another partner — Celgene — in a deal capitalizing on the industry appetite for TCR therapies and their potential to target solid tumors — a limitation of existing cellular therapies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.